MEDIOS

Fact Sheet

Contact:
ir@medios.group
www.medios.group

Company Profile

Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.

Executive Board

Thomas Meier, CEO

Stefan Bauerreis, CFO

Christoph Prusseit, CBO[1] Germany

Constantijn van Rietschoten, CBO[1] International

Structure and Segments

PHARMACEUTICAL SUPPLY

- Highly focused on Specialty Pharma drugs
- 1,000 products available

PATIENT-SPECIFIC THERAPIES

- Strongly positioned in patient-specific medication

INTERNATIONAL BUSINESS

- Leading full-service compounding services platform

FY[2] 2025 EBITDA pre[3] split[4]



Consolidated Revenue in €m



Consolidated EBITDA pre[3] in €m



[1] CBO = Chief Business Officer, [2] Full Year; [3] adjusted for extraordinary expenses (EBITDA pre); [4] Including the segment "Services" (–13% in FY 2025); [5] CAGR = Compound Annual Growth Rate; *adjusted for extraordinary expenses

Fact Sheet

Contact:
ir@medios.group
www.medios.group

Key Figures

in €m	2024 (IFRS)	2023 (IFRS)	Change
Revenue	2,078.7	1,883.0	*+10.4 %*
EBITDA pre*	93.1	79.0	*+17.8 %*
Margin in %	*4.5*	*4.2*	*+0.3 pp*

*adjusted for extraordinary expenses

Basic Information

Share Capital	€25,505,723
No. of shares	25,505,723
Share class	No-par value bearer shares
WKN / ISIN	A1MMCC / DE000A1MMCC8
Trading places	Regulated Market Frankfurt (Prime Standard), SDAX

Shareholder Structure

All figures according to voting rights notifications of the notifying parties

65.2%
Free float[1]
- 6.4% Janus Henderson
- 6.1% Axxion
- 3.9% Treasury Shares[2]
- 2.99% SEB Investment
- 2.4% Paladin Asset Management



19.7%
Martin Hesse[3]
incl. attribution of BMSH GmbH

15.1%
Luxempart Invest S.á.r.l.

[1] Free Float as defined by Deutsche Börse Group
[2] Treasury shares from the share buy-back offer do not carry voting or dividend rights (treasury shares as of July 17, 2025: 1,000,000 shares)
[3] Incl. attribution of BMSH GmbH

Share Price in €